The influence of human immunodeficiency virus (HIV) infection and vaccination schedule on the immunogenicity of a hepatitis A vaccine was examined. Ninety HIV-infected homosexual men received two vaccinations with hepatitis A vaccine (each 2 mL of 720 ELISA units/mL) either 1 or 6 months apart; 44 HIV-uninfected men received vaccine at study entry and at 6 months. Antihepatitis A virus (HAV) titer after vaccination was measured in 83 HIV-positive and 39 HIVnegative men. Seroconversion (anti-HAV antibody §20 IU/L) after two vaccinations occurred more frequently in HIV-negative men (100% vs. 88.2%; P Å .03). Anti-HAV titer after two vaccinations was also significantly greater in HIV-negative men (1086 vs. 101 IU/L; P Å .0001). HIV-positive men who responded to vaccination had significantly more CD4 lymphocytes (mean, 540/mL) at baseline than those who did not (280/mL; P Å .033). Vaccine schedule did not affect response. Vaccination of susceptible patients against HAV should be recommended early in HIV infection using the shorter course to encourage compliance.
In the past 6 years, significant epidemics of hepatitis A have homosexual men who are also at increased risk of HIV. Among homosexual men with acute hepatitis A during the Sydney occurred in the homosexual communities of New York, San Francisco, Toronto, Melbourne, Sydney, and elsewhere [1] [2] [3] .
epidemic of 1991, 27% were coinfected with HIV [3] . In order to examine the influence of HIV infection, HIVFor homosexual men, the risk of infection with hepatitis A virus (HAV) is increased by higher numbers of sex partners related immune depression, and vaccine schedule on the immunogenicity of an inactivated hepatitis A vaccine, a double dose and by certain sex practices that facilitate the ingestion of feces. These practices, such as oroanal contact, are often adopted to (2 mL of 720 ELU/mL) was administered to 90 HIV-positive and 44 HIV-negative homosexual men. The study was conreduce the risk of acquiring the human immunodeficiency virus (HIV) but may be particularly efficient for the transmission of ducted between August 1993 and June 1995. HAV. In 1991, a safe and effective whole virion vaccine for hepatitis A became available [4] . This vaccine induces protecMethods tive levels of anti-HAV antibody in virtually 100% of immunocompetent adults when given according to the recommended Study population. Subjects were homosexual men with known schedule of 720 ELISA units (ELU) at 0, 1, and 6 months [4] .
HIV antibody status attending one of two sexually transmitted However, many other vaccines, including those against indisease clinics in Sydney. Excluded were men who tested positive fluenza [5] , tetanus [5, 6] , pneumococcal infection [5, 6] , and for anti-HAV antibody at screening, had received human immunohepatitis B [7, 8] , have been shown to be less effective in HIVglobulin in the previous 9 months, or were receiving immunosupinfected persons, thereby potentially limiting their utility for pressive medication.
Vaccine. The vaccine used was a double dose of the licensed inactivated whole virion hepatitis A vaccine (Havrix; SmithKline Beecham Biologicals, Rixensart, Belgium). Two 1-mL vials each tered by the same injection into the deltoid muscle. respond were similar with respect to age, weight, and study
Statistics. The proportion of subjects developing protective ansite (data not shown). tibody were compared using x 2 or, where inappropriate, Fisher's exact method. Antibody titers were compared using the MannThe GMT of anti-HAV antibody was also greater in HIVWhitney U test. Calculation of geometric mean titer (GMT) innegative men than in HIV-positive men (table 2) . HIV-positive cluded subjects with no antibody response. Other continuous varimen with §200 CD4 cells/mL at baseline had higher GMTs ables were compared using a 2-tailed t test.
(130 IU/L) after two vaccinations than subjects with õ200 CD4 cells/mL (20 IU/L; P Å .0001). Vaccine schedule did not significantly affect response. Seroconversion was observed in Results 93.3% of HIV-infected men assigned the shorter 0, 1-month Study subjects. We recruited 136 homosexual men; 90 dose compared with 81.8% assigned the longer 0, 6-month were HIV-positive and 46 were HIV-negative. Of these, 134 schedule. (90 HIV-positive) received vaccine at least once, and 121 (82 Safety. The vaccine was generally well tolerated. Local HIV-positive) received vaccine twice. Anti-HAV titer after soreness was the most common side effect, reported by 10% vaccination was obtained for 122 participants (83 HIV-positive of HIV-positive and 9% of HIV-negative men. Mild systemic and 39 HIV-negative). HIV-negative men were similar in age symptoms such as headache, rash, nausea, lightheadedness, and and weight to their HIV-positive counterparts. There were no myalgia were reported by a further 33% of HIV-positive and significant differences among HIV-positive men on different 15% of HIV-negative men. vaccine schedules with respect to age, weight, clinical status, Discussion or CD4 cell count (table 1) .
Anti-HAV response. Among HIV-negative men, seroconIn this study, vaccination with two double doses of vaccine (720 ELU) resulted in a protective serologic response in 88% of version occurred 1 month after the first and second vaccinations HIV-infected homosexual men. These results reflect somewhat examine antibody decline; however, if anti-HAV is lost more quickly with HIV infection (as has been observed following greater success than was reported for the single dose in HIVinfected hemophiliacs (76%) [10] and homosexual men (77%) vaccination against hepatitis B [15] ), then the titer of anti-HAV might rapidly decline to below protective levels. Further [11] and far greater success than the 30%-50% response rates usually reported for hepatitis B vaccination in HIV-infected research on the rate of antibody decline in HIV infection is needed before any recommendations for booster vaccinations adults [7, 8] . Although this study did not directly compare the 720 and 1440 ELU doses, these findings suggest a greater can be made. Meanwhile, anti-HAV titer should be estimated regularly for HIV-positive persons following vaccination. immunogenicity with the larger dose in HIV-infected adults than has been seen in immunocompetent populations [12, 13] .
A nonsignificant trend towards a better response was seen with the shorter course (93% vs. 82%), but this may be due in Published data assessing the association of CD4 cell count with the response to vaccination against other pathogens in part to a greater mean baseline CD4 cell count (569 vs. 454/ mL). Dose-response studies in larger populations are needed HIV-positive study participants have reflected disparate results. In some studies, vaccination against hepatitis B [7] , influenza before the 0, 1-month schedule can be recommended to encourage compliance and to provide earlier protection. [5] , tetanus [5, 6] , and Streptococcus pneumoniae [5] was more successful in participants with higher CD4 cell counts, but this
The 1440 ELU dose was very well tolerated in this population, with no novel, severe, or unusual reactions reported. Headassociation was not seen in other studies of hepatitis B [8] and hepatitis A [11] vaccines. In our population of HIV-infected ache, myalgia, and nausea were all reported more frequently by HIV-infected persons but probably represent the underlying homosexual men, a high CD4 cell count correlated with both an increased chance of seroconversion and a higher mean titer disease. of anti-HAV antibody. A similar association was observed by Wilde et al. [14] in HIV-infected hemophiliacs but not in the homosexual men studied by Hess et al. [11] . However, the
